ACAD Acadia Pharmaceuticals PE ratio, current and historical analysis

?
Relative Growth: Rel. Growth: 77
Relative Strength: Rel. Strength: 70
Relative Valuation: Rel. Valuation: 73
Relative Profitability: Rel. Profitability: 93

The P/E ratio for Acadia Pharmaceuticals stock stands at 12.61 as of Aug 13, 2026. The calculation is based on the latest EPS of $2.25 and the stock price of $28.38 per share. An increase of 9% has been observed in the PE ratio compared to its average of 11.6 of the past four quarters.

ACAD PE ratio history

How has ACAD's PE ratio performed in the past

Over the last three years, the average PE ratio of Acadia Pharmaceuticals has been 21.98. The current 12.61 price-to-earnings ratio is 43% less than the historical average. Analyzing the last three years, ACAD's PE ratio reached its highest point in the Jun 2024 quarter at 90.28, with a price of $16.25 and an EPS of $0.18. The Mar 2026 quarter saw the lowest point at 9.98, with a price of $22.26 and an EPS of $2.23.

Today
12.61
Average
21.98
Median
13.39
Minimum
9.98
Maximum
90.28

Acadia Pharmaceuticals PE ratio by year

Maximum annual decrease: -14.04% in 2025

Year PE ratio PE change Price EPS
2025 11.51 -14.04% $26.71 $2.32
2024 13.39 N/A $18.35 $1.37
2023 N/A N/A $31.31 -$0.37
2022 N/A N/A $15.92 -$1.34
2021 N/A N/A $23.34 -$1.05
2020 N/A N/A $53.46 -$1.79
2019 N/A N/A $42.78 -$1.6
2018 N/A N/A $16.17 -$1.94
2017 N/A N/A $30.11 -$2.36
2016 N/A N/A $28.84 -$2.34
2015 N/A N/A $35.65 -$1.63
2014 N/A N/A $31.75 -$0.95
2013 N/A N/A $24.99 -$0.44
2012 N/A N/A $4.65 -$0.38
2011 N/A N/A $1.08 -$0.44

Acadia Pharmaceuticals PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Jun 2026 11.24 12.63% $25.3 $2.25
Mar 2026 9.98 -13.29% $22.26 $2.23
Dec 2025 11.51 -15.31% $26.71 $2.32
Sep 2025 13.59 -15.59% $21.34 $1.57
Jun 2025 16.1 33.72% $21.57 $1.34
Mar 2025 12.04 -10.08% $16.61 $1.38
Dec 2024 13.39 -32.1% $18.35 $1.37
Sep 2024 19.72 -78.16% $15.38 $0.78
Jun 2024 90.28 N/A $16.25 $0.18
Mar 2024 N/A N/A $18.49 -$0.01
Dec 2023 N/A N/A $31.31 -$0.37
Sep 2023 N/A N/A $20.84 -$0.92
Jun 2023 N/A N/A $23.95 -$0.69
Mar 2023 N/A N/A $18.82 -$0.91
Dec 2022 N/A N/A $15.92 -$1.34

ACAD Price vs fair value

How does ACAD's price compare to its estimated fair value based on its growth

ACAD average PE ratio chart

What is the average PE ratio of ACAD for the past years

Currently, ACAD's PE ratio is under its 3, 5 and 10-year averages.

3-year avg
21.98
5-year avg
21.98
10-year avg
21.98
15-year avg
20.04

PE comparison

Acadia Pharmaceuticals's price to earnings (P/E) of 12.61 is lower than the Healthcare sector, the industry and its peers average. Looking at the Healthcare sector average of 24.28, Acadia Pharmaceuticals's price to earnings (P/E) is 48% lower.

ACAD PE vs peers

What is ACAD's PE ratio compared to its peers

Frequently asked questions

What is Acadia Pharmaceuticals's PE ratio?

The price to earnings ratio for ACAD stock as of Aug 13, 2026, stands at 12.61.

What is the 3-year average PE ratio for Acadia Pharmaceuticals (ACAD)?

As an average over the last 3 years, ACAD stock has a PE ratio of 21.98.

What is the 5-year average PE ratio for Acadia Pharmaceuticals (ACAD)?

As an average over the last 5 years, ACAD stock has a PE ratio of 21.98.

What is the highest PE ratio for ACAD?

The highest quarterly PE ratio in the last three years has been 90.28 and it was in the Jun 2024 quarter.

How does the current PE ratio for ACAD compare to its historical average?

ACAD's current price to earnings ratio is 43% below its 3-year historical average.

How is ACAD's PE ratio calculated (Acadia Pharmaceuticals PE ratio formula)?

To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Aug 13, 2026), Acadia Pharmaceuticals's share price is $28.38. The company's earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $2.25. Therefore, Acadia Pharmaceuticals's price to earnings ratio for today is 12.61. PE RATIO(12.61) = STOCK PRICE($28.38) / TTM EPS($2.25)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.